{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T01:33:12Z","timestamp":1712107992640},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,2]]},"DOI":"10.7759\/cureus.57447","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T13:48:06Z","timestamp":1712065686000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Effectiveness and Safety of Direct-Acting Oral Anticoagulants and Vitamin K Agonists in Patients With Atrial Fibrillation and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Tanya","family":"Sinha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abshiro H","family":"Mayow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taslova Tahsin","family":"Abedin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaw N","family":"Phoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saima H","family":"Shawl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer","family":"Kholoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamsha","family":"Hirani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1060096","article-title":"Atrial fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 2","volume":"9","author":"Trohman RG","year":"2022","unstructured":"Trohman RG, Huang HD, Sharma PS. Atrial fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 2. Front Cardiovasc Med. 2022, 9:1060096. 10.3389\/fcvm.2022.1060096","journal-title":"Front Cardiovasc Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and Stroke Statistics-2021 update: a report from the American Heart Association","volume":"143","author":"Virani SS","year":"2021","unstructured":"Virani SS, Alonso A, Aparicio HJ, et al.. Heart disease and Stroke Statistics-2021 update: a report from the American Heart Association. Circulation. 2021, 143:e254-743. 10.1161\/CIR.0000000000000950","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0.","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff CT","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al.. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet North Am Ed. 2014, 383:955-62. 10.1016\/S0140-6736(13)62343-0.","journal-title":"Lancet North Am Ed"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12652","article-title":"Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study","volume":"12","author":"Christiansen CF","year":"2014","unstructured":"Christiansen CF, Schmidt M, Lamberg AL, Horv\u00e1th-Puh\u00f3 E, Baron JA, Jespersen B, S\u00f8rensen HT. Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study. J Thromb Haemost. 2014, 12:1449-54. 10.1111\/jth.12652","journal-title":"J Thromb Haemost"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.029680","article-title":"Chronic kidney disease and cerebrovascular disease: consensus and guidance from a KDIGO controversies conference","volume":"52","author":"Kelly DM","year":"2021","unstructured":"Kelly DM, Ademi Z, Doehner W, et al.. Chronic kidney disease and cerebrovascular disease: consensus and guidance from a KDIGO controversies conference. Stroke. 2021, 52:e328-46. 10.1161\/STROKEAHA.120.029680","journal-title":"Stroke"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa216","article-title":"Bleeding risk of haemodialysis and peritoneal dialysis patients","volume":"36","author":"van Eck van der Sluijs A","year":"2021","unstructured":"van Eck van der Sluijs A, Abrahams AC, Rookmaaker MB, et al.. Bleeding risk of haemodialysis and peritoneal dialysis patients. Nephrol Dial Transplant. 2021, 36:170-5. 10.1093\/ndt\/gfaa216","journal-title":"Nephrol Dial Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2016.09.016","article-title":"Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis","volume":"184","author":"Van Der Meersch H","year":"2017","unstructured":"Van Der Meersch H, De Bacquer D, De Vriese AS. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis. Am Heart J. 2017, 184:37-46. 10.1016\/j.ahj.2016.09.016","journal-title":"Am Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.08.1031","article-title":"Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week","volume":"74","author":"Kumar S","year":"2019","unstructured":"Kumar S, Lim E, Covic A, Verhamme P, Gale CP, Camm AJ, Goldsmith D. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol. 2019, 74:2204-15. 10.1016\/j.jacc.2019.08.1031","journal-title":"J Am Coll Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020967635","article-title":"Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism: a systematic review of thrombosis and bleeding outcomes","volume":"55","author":"Cheung CY","year":"2021","unstructured":"Cheung CY, Parikh J, Farrell A, Lefebvre M, Summa-Sorgini C, Battistella M. Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism: a systematic review of thrombosis and bleeding outcomes. Ann Pharmacother. 2021, 55:711-22. 10.1177\/1060028020967635","journal-title":"Ann Pharmacother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6419147","article-title":"Apixaban in comparison to warfarin for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies","volume":"2019","author":"Siddiqui MU","year":"2019","unstructured":"Siddiqui MU, Scalzitti D, Naeem Z. Apixaban in comparison to warfarin for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Cardiol Res Pract. 2019, 2019:6419147. 10.1155\/2019\/6419147","journal-title":"Cardiol Res Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis","volume":"131","author":"Chan KE","year":"2015","unstructured":"Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015, 131:972-9. 10.1161\/CIRCULATIONAHA.114.014113","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177691","article-title":"Stroke and bleeding in patients with atrial fibrillation and end-stage renal disease treated with apixaban versus warfarin","volume":"142","author":"Lara JM","year":"2023","unstructured":"Lara JM, Dourado C. Stroke and bleeding in patients with atrial fibrillation and end-stage renal disease treated with apixaban versus warfarin. Blood. 2023, 142:2638. 10.1182\/blood-2023-177691","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249940","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: a real-world nationwide cohort study","volume":"16","author":"Lin YC","year":"2021","unstructured":"Lin YC, Chen BL, Shih CM, et al.. Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: a real-world nationwide cohort study. PLoS One. 2021, 16:e0249940. 10.1371\/journal.pone.0249940","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2023.12.020","article-title":"Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis","volume":"64","author":"Moore M","year":"2024","unstructured":"Moore M, Vizcaino K, Ewing JA, St Ville M. Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis. J Am Pharm Assoc (2003). 2024, 64:457-62. 10.1016\/j.japh.2023.12.020","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2016.04.026","article-title":"Stroke and bleeding risks in NOAC-and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation","volume":"67","author":"Noseworthy PA","year":"2016","unstructured":"Noseworthy PA, Yao X, Shah ND, Gersh BJ. Stroke and bleeding risks in NOAC-and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation. J Am Coll Cardiol. 2016, 67:3020-1.","journal-title":"J Am Coll Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney SD","year":"2022","unstructured":"Pokorney SD, Chertow GM, Al-Khalidi HR, et al.. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation. 2022, 146:1735-45. 10.1161\/CIRCULATIONAHA.121.054990","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist Phenprocoumon in patients on chronic hemodialysis: the Axadia-AFNET 8 study","volume":"147","author":"Reinecke H","year":"2023","unstructured":"Reinecke H, Engelbertz C, Bauersachs R, et al.. A randomized controlled trial comparing apixaban with the vitamin K antagonist Phenprocoumon in patients on chronic hemodialysis: the Axadia-AFNET 8 study. Circulation. 2023, 147:296-309. 10.1161\/CIRCULATIONAHA.122.062779","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-07108-4","article-title":"Effectiveness and safety of direct oral anticoagulants in an Asian population with atrial fibrillation undergoing dialysis: a population-based cohort study and meta-analysis","volume":"35","author":"See LC","year":"2021","unstructured":"See LC, Lee HF, Chao TF, et al.. Effectiveness and safety of direct oral anticoagulants in an Asian population with atrial fibrillation undergoing dialysis: a population-based cohort study and meta-analysis. Cardiovasc Drugs Ther. 2021, 35:975-86. 10.1007\/s10557-020-07108-4","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis KC","year":"2018","unstructured":"Siontis KC, Zhang X, Eckard A, et al.. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018, 138:1519-29. 10.1161\/CIRCULATIONAHA.118.035418","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019060579","article-title":"Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie study","volume":"31","author":"De Vriese AS","year":"2020","unstructured":"De Vriese AS, Caluw\u00e9 R, Pyfferoen L, et al.. Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie study. J Am Soc Nephrol. 2020, 31:186-96. 10.1681\/ASN.2019060579","journal-title":"J Am Soc Nephrol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad004","article-title":"Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D","volume":"16","author":"Welander F","year":"2023","unstructured":"Welander F, Renlund H, Dim\u00e9ny E, Holmberg H, Sj\u00e4lander A. Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D. Clin Kidney J. 2023, 16:835-44. 10.1093\/ckj\/sfad004","journal-title":"Clin Kidney J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27838","article-title":"Comparison of the efficacy and safety of apixaban and warfarin in the prevention of stroke in patients with non-valvular atrial fibrillation: a meta-analysis","volume":"14","author":"Memon RA","year":"2022","unstructured":"Memon RA, Hamdani SS, Usama A, et al.. Comparison of the efficacy and safety of apixaban and warfarin in the prevention of stroke in patients with non-valvular atrial fibrillation: a meta-analysis. Cureus. 2022, 14:e27838. 10.7759\/cureus.27838","journal-title":"Cureus"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2020.09.041","article-title":"Safety and efficacy of apixaban, rivaroxaban, and warfarin in end-stage renal disease with atrial fibrillation: a systematic review and meta-analysis","volume":"30","author":"Abdullah HM","year":"2021","unstructured":"Abdullah HM, Ullah W, Jafar MS, et al.. Safety and efficacy of apixaban, rivaroxaban, and warfarin in end-stage renal disease with atrial fibrillation: a systematic review and meta-analysis. Cardiovasc Revasc Med. 2021, 30:26-32. 10.1016\/j.carrev.2020.09.041","journal-title":"Cardiovasc Revasc Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbs1403021","article-title":"Direct oral anticoagulants in patients on chronic dialysis and concomitant atrial fibrillation: a common clinical impasse","volume":"14","author":"Ktenopoulos N","year":"2022","unstructured":"Ktenopoulos N, Sagris M, Theofilis P, Lionaki S, Rallidis LS. Direct oral anticoagulants in patients on chronic dialysis and concomitant atrial fibrillation: a common clinical impasse. Front Biosci (Schol Ed). 2022, 14:21. 10.31083\/j.fbs1403021","journal-title":"Front Biosci (Schol Ed)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.11.032","article-title":"Warfarin and vascular calcification","volume":"129","author":"Poterucha TJ","year":"2016","unstructured":"Poterucha TJ, Goldhaber SZ. Warfarin and vascular calcification. Am J Med. 2016, 129:635.e1-4. 10.1016\/j.amjmed.2015.11.032","journal-title":"Am J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316341","article-title":"Population-based screening for atrial fibrillation","volume":"127","author":"Khurshid S","year":"2020","unstructured":"Khurshid S, Healey JS, McIntyre WF, Lubitz SA. Population-based screening for atrial fibrillation. Circ Res. 2020, 127:143-54. 10.1161\/CIRCRESAHA.120.316341","journal-title":"Circ Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017. 02.004\u00a0","article-title":"Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and metaanalysis","volume":"33","author":"Harel Z","year":"2017","unstructured":"Harel Z, Chertow GM, Shah PS, et al.. Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and metaanalysis. Can J Cardiol. 2017, 33:737-46. 10.1016\/j.cjca.2017. 02.004\u00a0","journal-title":"Can J Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017694654","article-title":"Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease","volume":"51","author":"Sarratt SC","year":"2017","unstructured":"Sarratt SC, Nesbit R, Moye R. Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease. Ann Pharmacother. 2017, 51:445-50. 10.1177\/1060028017694654","journal-title":"Ann Pharmacother"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.08.047","article-title":"Removal of dabigatran by hemodialysis","volume":"61","author":"Chang DN","year":"2013","unstructured":"Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013, 61:487-9. 10.1053\/j.ajkd.2012.08.047","journal-title":"Am J Kidney Dis"},{"key":"ref30","unstructured":"Oral anticoagulation in haemodialysis patients (AVKDIAL). (2016). Accessed. September 14, 2021: https:\/\/clinicaltrials.gov\/ct2\/ show\/NCT02886962."},{"key":"ref31","unstructured":"Strategies for the management of atrial fibrillation in patients receiving dialysis (SAFE-D). (2021). Accessed. July 23, 2021:  https:\/\/ clinicaltrials.gov\/ct2\/show\/NCT03987711."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/241616-comparison-of-effectiveness-and-safety-of-direct-acting-oral-anticoagulants-and-vitamin-k-agonists-in-patients-with-atrial-fibrillation-and-end-stage-kidney-disease-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T13:48:10Z","timestamp":1712065690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/241616-comparison-of-effectiveness-and-safety-of-direct-acting-oral-anticoagulants-and-vitamin-k-agonists-in-patients-with-atrial-fibrillation-and-end-stage-kidney-disease-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.57447","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,2]]}}}